Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicenter study of TL-895 in relapsed/refractory, JAK inhibitor-intolerant, or JAK inhibitor-ineligible myelofibrosis
MOH_2021-12-08_010451Phase 2Completed
- Sponsor
- Telios Pharma
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TL-895 in myelofibrosis (MF) (6 cohorts), sponsored by Telios Pharma. Started Nov 2021; status: completed.
02
Drugs
TL-895
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2021-12-08_010451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-08_010451.